FcR-mediated enhancement of HIV-1 infection by antibody. NLM AIDSLINE Important note: Information in this article was accurate in 1991. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


FcR-mediated enhancement of HIV-1 infection by antibody.

AIDS Res Hum Retroviruses. 1990 Aug;6(8):999-1004. Unique Identifier : AIDSLINE MED/91026280
Takeda A; Ennis FA; Department of Medicine, University of Massachusetts Medical; School, Worcester 01655.


Abstract: Although CD4 is a major receptor for human immunodeficiency virus (HIV) infection of cells, studied by ourselves and others clearly show that the Fc receptor (FcR) also plays a role in infection, perhaps in conjunction with other surface receptors. IgG antibodies to HIV-1 will enhance infectivity in cells (such as monocyte-macrophages) that have surface Fc receptors; F(ab')2 fragments of antibodies did not enhance, and blocking of FcR inhibited enhancement. The high-affinity FcR for IgG (Fc gamma RI) appeared to be functional. Sera from HIV-1-infected patients had neutralizing activity at high concentrations, but enhanced infection at low concentrations (i.e., high dilutions). Our studies show that the CD4 receptor is required for antibody-mediated enhancement of infection, as enhancement can be blocked by recombinant soluble CD4 and by Leu3 antibody. Although enhancement can be demonstrated in vitro, the in vivo importance of enhancing antibodies remains to be defined in HIV-1 infection.
Keywords: Acquired Immunodeficiency Syndrome/*ETIOLOGY Antigens, CD4/PHYSIOLOGY Human HIV Antibodies/*PHYSIOLOGY HIV-1/*PATHOGENICITY Receptors, Fc/*PHYSIOLOGY Support, U.S. Gov't, Non-P.H.S. Support, U.S. Gov't, P.H.S. JOURNAL ARTICLE REVIEW REVIEW LITERATUREKWDacquiredimmunodeficiencysyndrome/KWDetiologyantigens,cd4/physiologyhumanhivantibodies/KWDphysiologyhiv-1/KWDpathogenicityreceptors,fc/KWDphysiologysupport,uKWDsKWDgov't,non-pKWDhKWDsKWDsupport,uKWDsKWDgov't,pKWDhKWDsKWDjournalarticlereviewreviewliterature
910228
M9120679

Copyright © 1991 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1991. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1991. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .